Clinical Data ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition Pharmaceutical TechnologyData from the REDEFINE-1 trial (NCT05567796) were recently presented in Turkiye, assessing Novo Nordisk's CagriSema in adults with obesity.Metabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Turkiye, assessing Novo Nordisk’s CagriSema in adults with obesity. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switchingNext: Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B Related Stories Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026 Clinical Data Major trial launched to explore GLP-1 benefit in dementia pharminent July 13, 2026 Clinical Data GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China pharminent July 10, 2026
